Plasma AR and abiraterone-resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Plasma AR and abiraterone-resistant prostate cancer

Published:2015-11-04 Issue:312 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Romanel Alessandro¹,Tandefelt Delila Gasi²,Conteduca Vincenza²³,Jayaram Anuradha²⁴,Casiraghi Nicola¹,Wetterskog Daniel²,Salvi Samanta³,Amadori Dino³,Zafeiriou Zafeiris²⁴,Rescigno Pasquale²⁴,Bianchini Diletta²⁴,Gurioli Giorgia³,Casadio Valentina³,Carreira Suzanne²,Goodall Jane²,Wingate Anna²⁴,Ferraldeschi Roberta²⁴,Tunariu Nina²⁴,Flohr Penny²,De Giorgi Ugo³,de Bono Johann S.²⁴,Demichelis Francesca¹⁵⁶,Attard Gerhardt²⁴

Affiliation:

1. Centre for Integrative Biology, University of Trento, Trento 38123, Italy.

2. The Institute of Cancer Research, London SW7 3RP, UK.

3. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy.

4. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK.

5. Institute for Computational Biomedicine, Weill Cornell Medicine, NY 10021, USA.

6. Institute for Precision Medicine, Weill Cornell Medicine, NY 10021, USA.

Abstract

Androgen receptor mutations and amplifications in circulating tumor DNA provide clues to prostate cancer drug resistance.

Funder

National Cancer Institute

Institute of Cancer Research (ICR) Biomedical Research Centre

Cancer Research UK

Cancer Research UK Clinician Scientist Fellowship

Prostate Cancer UK

Movember Global Action Plan

NIHR Royal Marsden

European Union Marie Curie Intra-European Postdoctoral Fellowship

European Society of Medical Oncology Translational Clinical Research Fellowship

Irish Health Research Board Clinical Research Fellowship

London Movember Prostate Cancer Centre

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference29 articles.

1. Abiraterone and Increased Survival in Metastatic Prostate Cancer

2. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

3. Integrative Clinical Genomics of Advanced Prostate Cancer

4. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response

5. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Cited by 385 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers;Frontiers in Oncology;2024-09-10

2. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial;European Urology Oncology;2024-09

3. Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed;Frontiers in Genetics;2024-07-31

4. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial;European Journal of Cancer;2024-07

5. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications;Cancers;2024-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3